- Argo will receive upfront payments of $185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.

-Argo将从诺华获得1.85亿美元的预付款，并有资格获得潜在的期权和里程碑付款以及商业销售的分层版税。

- Novartis will receive an ex-Greater China exclusive license for a Phase 1/2a stage cardiovascular asset, a worldwide exclusive license for a Phase 1 stage cardiovascular asset as well as an option to license compounds directed against up to two cardiovascular targets.

-诺华将获得1/2a期心血管资产的前大中华区独家许可证，1期心血管资产的全球独家许可证，以及针对多达两个心血管靶标的化合物的许可选择权。

- Discovered and developed with Argo's advanced RNA interference (RNAi) technology, these programs will reinforce and expand the Novartis RNAi portfolio on Cardiovascular and Metabolic diseases (CVM).

-通过Argo的先进RNA干扰（RNAi）技术发现和开发，这些计划将加强和扩大诺华在心血管和代谢疾病（CVM）方面的RNAi组合。

SHANGHAI, Jan. 7, 2024 /PRNewswire/ -- Shanghai Argo Biopharmaceutical Co., Ltd. ('Argo'), a biotechnology company focused on the discovery and development of next-generation RNAi therapeutics, today announced that it has entered into two exclusive license and collaboration agreements with Novartis PHARMA AG ('Novartis')..

上海，2024年1月7日/PRNewswire/--专注于发现和开发下一代RNAi治疗剂的生物技术公司上海阿尔戈生物制药有限公司（“阿尔戈”）今天宣布，它已与诺华制药公司（“诺华”）签订了两项独家许可和合作协议。。

Under the first agreement, Argo has granted Novartis exclusive global licenses to develop and commercialize a Phase 1 stage program. The first agreement also includes a research collaboration and Novartis also receives an option to potentially license compounds directed against up to two additional targets for cardiovascular disease treatment.

根据第一份协议，Argo已授予诺华独家全球许可证，以开发和商业化第一阶段项目。第一份协议还包括一项研究合作，诺华还可以选择针对多达两个额外的心血管疾病治疗靶点的潜在许可化合物。

Under the second agreement, Argo granted Novartis an exclusive ex-Greater China license to develop and commercialize a Phase 1/2a clinical-stage program for cardiovascular disease treatment. .

根据第二份协议，Argo授予诺华独家前大中华区许可证，用于开发和商业化心血管疾病治疗的1/2a期临床阶段计划。。

Discovered and developed with Argo's cutting-edge RNAi platform technology, these clinical-stage assets offer industry-leading efficacy and durability therapies. The transactions have a combined potential value of up to $4.165 billion for Argo and tiered royalties.

这些临床阶段资产是通过Argo的尖端RNAi平台技术发现和开发的，可提供业界领先的疗效和耐久性疗法。这些交易对Argo和分层版税的合并潜在价值高达41.65亿美元。

'This is the first significant overseas out-licensing transaction in the RNAi field from a Chinese biotech company. We are pleased that Novartis, a global leader in cardiovascular disease and RNAi therapeutics, recognizes the significant value that the Argo team has created with advanced RNAi platform technology and new generation CVM pipeline over the past two years.' said Dongxu Shu, president and chief executive officer of Argo Biopharma.

“这是中国生物技术公司在RNAi领域的首次重大海外授权交易。我们很高兴，心血管疾病和RNAi治疗领域的全球领导者诺华认识到Argo团队在过去两年中利用先进的RNAi平台技术和新一代CVM管道创造的巨大价值。”Argo Biopharma总裁兼首席执行官董旭曙表示。

'The proven development capabilities, global commercial reach, and breadth of experience Novartis has in CVM make it the ideal partner to accelerate the development of our drug candidates and bring these medicines to patients'..

“诺华在CVM方面拥有成熟的开发能力、全球商业影响力和丰富的经验，使其成为加速我们候选药物开发并将这些药物带给患者的理想合作伙伴”。。

'We believe the cardiovascular programs that Argo has developed using its state-of-the-art RNAi platform complement the Novartis pipeline of RNA-based therapeutics,' said Shaun Coughlin, Head of Cardiovascular and Metabolic Disease Area research at Novartis. 'We look forward to working with Argo to bring these investigational therapies forward to help address unmet patient needs in cardiovascular medicine.'.

诺华心血管和代谢疾病领域研究负责人肖恩·考夫林（ShaunCoughlin）说：“我们相信，Argo利用其最先进的RNAi平台开发的心血管项目补充了诺华基于RNA的治疗方法。”我们期待着与Argo合作，推动这些研究疗法的发展，以帮助解决心血管医学中未满足的患者需求。”。

Also under the first agreement, Novartis can select up to two targets against which Argo will perform discovery and optimization, to deliver PCCs, at which time Novartis will have the option to take a worldwide exclusive license.

同样根据第一份协议，诺华可以选择最多两个目标，Argo将针对这两个目标进行发现和优化，以交付PCC，届时诺华将有权获得全球独家许可。

The second transaction is subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act.

第二笔交易需要根据哈特·斯科特·罗迪诺反托拉斯改进法案进行审批。

About Shanghai Argo Biopharmaceutical Co., Ltd.

关于上海阿尔戈生物制药有限公司。

Founded in April 2021, Argo is a privately held biotechnology company based in Shanghai. The company's primary focus is on RNAi drug research and development. Argo has developed industry-leading RNAi platform technology named RADS (RNAi molecules with superior Activity, Duration and Safety), which embodies Argo's technological prowess in delivery, chemical modification, and sequence designs, consistently yielding top-tier RNAi therapeutics..

Argo成立于2021年4月，是一家总部位于上海的私营生物技术公司。该公司的主要重点是RNAi药物的研究和开发。Argo开发了业界领先的RNAi平台技术RADS（具有优异活性，持续时间和安全性的RNAi分子），它体现了Argo在递送，化学修饰和序列设计方面的技术实力，始终产生顶级RNAi治疗剂。。

Argo's present pipeline includes more than 20 therapeutic programs for the treatment of cardiovascular and metabolic diseases, hematology, complement pathway diseases, viral infection and neurodegenerative diseases. Five leading programs are in the clinical development stage, and all have demonstrated well-tolerated safety profiles and best-in-class potential..

Argo目前的管道包括20多种治疗方案，用于治疗心血管和代谢疾病、血液学、补体途径疾病、病毒感染和神经退行性疾病。五个领先的项目处于临床开发阶段，所有项目都表现出良好的耐受性安全性和一流的潜力。。

Additional information about Argo is available at www.argobiopharma.com.

有关Argo的更多信息，请访问www.argobiopharma.com。

SOURCE Shanghai Argo Biopharmaceutical Co., Ltd.

来源上海阿尔戈生物制药有限公司。